Qlaris’ QLS-111 Shows Positive IOP-Lowering Results in Phase II Glaucoma Trials
The drug met all primary and secondary endpoints in the Osprey and Apteryx studies with an excellent safety and tolerability….
The drug met all primary and secondary endpoints in the Osprey and Apteryx studies with an excellent safety and tolerability….